Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy
摘要:
The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption, Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 mu M) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.
Synthesis of Substituted Pyridines by a Cycloaddition Route Using Nitrile Oxides and Homoallyl Alcohols
作者:Shuji Kanemasa、Yoshihiko Asai、Junji Tanaka
DOI:10.1246/bcsj.64.375
日期:1991.2
Cycloadditions of nitrile oxides with unprotected homoallyl alcohols, followed by Swern oxidations, lead to 5-(2-oxoalkyl)-2-isoxazolines. Subsequent Raney Ni reduction of the resulting heterocycles in ethanol in the presence of excess tetrafluoroboric acid affords substituted pyridine derivatives.
腈氧化物与未保护的高烯丙醇的环加成,然后是 Swern 氧化,产生 5-(2-氧代烷基)-2-异恶唑啉。随后在过量四氟硼酸存在下,在乙醇中对所得杂环进行 Raney Ni 还原,得到取代的吡啶衍生物。
KANEMASA, SHUJI;ASAI, YOSHIHIKO;TANAKA, JUNJI, BULL. CHEM. SOC. JAP., 64,(1991) N, C. 375-380
作者:KANEMASA, SHUJI、ASAI, YOSHIHIKO、TANAKA, JUNJI
DOI:——
日期:——
Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy
作者:Dale J. Kempf、Hing L. Sham、Kennan C. Marsh、Charles A. Flentge、David Betebenner、Brian E. Green、Edith McDonald、Sudthida Vasavanonda、Ayda Saldivar、Norman E. Wideburg、Warren M. Kati、Lisa Ruiz、Chen Zhao、LynnMarie Fino、Jean Patterson、Akhteruzzaman Molla、Jacob J. Plattner、Daniel W. Norbeck
DOI:10.1021/jm970636+
日期:1998.2.1
The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption, Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 mu M) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.